Wiedemann–Steiner syndrome

Rare genetic disorder involving developmental delay and facial dysmorphism

Wiedemann–Steiner syndrome
Synonyms	Hypertrichosis-short stature-facial dysmorphism-developmental delay syndrome
Pronounce
Specialty	N/A
Symptoms	Developmental delay, short stature, hypotonia, facial dysmorphism, hypertrichosis
Complications	Delayed milestones, speech delays, intellectual disability
Onset	Congenital (present at birth)
Duration	Lifelong
Types
Causes	Mutations in the KMT2A gene
Risks	De novo mutation or inherited in an autosomal dominant manner
Diagnosis	Clinical evaluation, whole exome sequencing
Differential diagnosis	Rubinstein–Taybi syndrome, Kabuki syndrome, Autism spectrum disorder
Prevention	None
Treatment	Supportive therapies (physical, occupational, speech)
Medication	Symptomatic only
Prognosis	Varies; developmental delays often persist
Frequency	Estimated 1 in 40,000
Deaths	Rare, not typically life-threatening

Wiedemann–Steiner syndrome (WSS) is a rare genetic disorder characterized by developmental delay, facial dysmorphism, short stature, and increased body hair, especially on the elbows. The condition is named after Hans-Rudolf Wiedemann and was first described in 1989. The genetic basis was later identified in 2012 by Dr. Wendy D. Jones.

Signs and symptoms

Individuals with Wiedemann–Steiner syndrome may present with a variety of clinical features including:

• Short stature
• Global developmental delay
• Low muscle tone (hypotonia), especially in infancy
• Facial dysmorphism (broad nasal bridge, long eyelashes, downslanting palpebral fissures)
• Hypertrichosis cubiti (excess hair on elbows)
• Dental abnormalities
• Sleep disorders
• Feeding difficulties in infancy
• Intellectual disability and behavioral challenges in some cases

The severity and combination of features vary significantly among individuals.

Cause

Wiedemann–Steiner syndrome is caused by mutations in the KMT2A gene (formerly known as MLL) located on the long arm of chromosome 11 (11q23). This gene encodes a histone methyltransferase, which plays a critical role in regulating gene expression during development.

WSS follows an autosomal dominant pattern of inheritance, meaning only one copy of the altered gene is sufficient to cause the disorder. In most reported cases, the mutation occurs de novo (spontaneously), meaning it is not inherited from either parent.

Diagnosis

Diagnosis of WSS is based on:

• Clinical evaluation and recognition of characteristic features
• Whole exome sequencing or genetic panel testing for the KMT2A gene

Challenges in diagnosis

• WSS is not detectable by standard prenatal screening tests
• Misdiagnosis as Kabuki syndrome, Rubinstein–Taybi syndrome, or autism spectrum disorder is common
• Many individuals remain undiagnosed or are diagnosed later in life due to the subtle and variable features
• Whole genome or exome sequencing is often required but may not be readily available or covered by insurance

Treatment

There is no cure for WSS. Management is supportive and tailored to individual needs:

• Physical therapy for motor delays
• Occupational therapy and speech therapy
• Feeding therapy in infancy
• Behavioral therapy for attention and emotional regulation
• Special education programs, one-on-one aides, and individualized education plans

Complementary therapies such as hippotherapy (horseback therapy) and music therapy have also shown benefit in some cases.

Prognosis

WSS is a lifelong condition. While developmental delays and intellectual disabilities are common, many individuals can achieve significant progress with early intervention and supportive therapies. Life expectancy is typically normal, and the condition is not known to be life-limiting.

Epidemiology

Wiedemann–Steiner syndrome is a rare disorder. Although it was initially estimated to affect 1 in 1,000,000 individuals, newer studies suggest the incidence may be closer to 1 in 40,000. Only a few hundred cases have been documented worldwide.

History

• Described by Hans-Rudolf Wiedemann in 1989
• Genetic cause identified by Dr. Wendy D. Jones in 2012
• Associated with mutations in KMT2A (MLL), a gene also involved in leukemia when somatically mutated

See also

• Rubinstein–Taybi syndrome
• Kabuki syndrome
• Intellectual disability
• Developmental delay
• Autosomal dominant inheritance
• Rare disease

External links

• Online Mendelian Inheritance in Man (OMIM) 605130

• Genetics Home Reference: Wiedemann–Steiner syndrome
• NORD Rare Disease Database: Wiedemann–Steiner syndrome